Vaccine against Meningococcal serotype B disease
Project 95
Problem to be solved:
- Severe public health problem
- High morbidity and mortality
- High incidence of meningococcal serotype B disease in Brazil
- Dependence on imported products
Proposed Innovation:
Protein vaccine against Meningococcal group B disease
Differential:
- Vaccine aims at serotype of great incidence in Brazil
- Use of detoxified endotoxin
- Clinical studies of phase I concluded
Development status:
Clinical
Intellectual property status:
No patent protection
Technology transfer status:
Prospecting partnership
Coordinator:
Ellen Jessouroun / Biomanguinhos
Contact:
Gestec/VPPIS – Phone: 21 3882-9099 / 3882-9120 or portfolio@fiocruz.br